The Phase 1/2 open-label, dose-escalation and expansion study ( NCT06667960 ) to assess the safety, pharmacokinetics, and preliminary efficacy of JK06 is ongoing, and the cohort expansion phase, which ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback